Screening for placenta accreta at 11-14 weeks of gestation

Am J Obstet Gynecol. 2011 Dec;205(6):547.e1-6. doi: 10.1016/j.ajog.2011.07.021. Epub 2011 Jul 22.

Abstract

Objective: We sought to describe the potential value of 11-14 weeks' screening for placenta accreta (PA).

Study design: Patients with a history of lower segment cesarean section were prospectively included between 11-13+6 weeks over a 1.5-year period. The first 258 were offered standard screening whereas the following 105 underwent screening for PA. Women were considered high-risk when the trophoblast overlapped the scar visualized by transvaginal ultrasound and low-risk otherwise.

Results: The group screened for PA did not differ from the nonscreened group for demographic characteristics. In all, 6 of 105 (5.8%) women were considered high-risk. In the nonscreened group, 1 case of PA was discovered during an elective repeat cesarean. In the screened population, 1 case of PA occurred in a high-risk patient allowing a conservative planned management at 35 weeks.

Conclusion: At 11-14 weeks, ultrasound may help risk stratification for PA with a specific follow-up. Early recognition of patients at risk might improve the perinatal outcome of PA.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cesarean Section / adverse effects
  • Cesarean Section / statistics & numerical data
  • Cicatrix / diagnostic imaging
  • Cicatrix / epidemiology
  • Female
  • Gestational Age
  • Humans
  • Mass Screening
  • Placenta Accreta / diagnostic imaging*
  • Placenta Accreta / epidemiology
  • Pregnancy
  • Pregnancy Trimester, First*
  • Prospective Studies
  • Risk Factors
  • Trophoblasts / diagnostic imaging
  • Ultrasonography, Prenatal*